icad inc. (NASDAQ:ICAD) released its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03, Bloomberg Earnings reports. icad inc. had a negative net margin of 34.74% and a negative return on equity of 44.39%. The firm had revenue of $6.41 million during the quarter, compared to analysts’ expectations of $6.41 million.
Shares of icad inc. (NASDAQ:ICAD) traded up 0.55% during mid-day trading on Friday, reaching $3.65. 83,330 shares of the company’s stock were exchanged. icad inc. has a one year low of $2.82 and a one year high of $6.49. The company’s market capitalization is $60.57 million. The company’s 50-day moving average price is $3.92 and its 200-day moving average price is $4.35.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Argent Capital Management LLC boosted its stake in icad inc. by 13.2% in the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock worth $2,990,000 after buying an additional 82,967 shares in the last quarter. Vanguard Group Inc. boosted its stake in icad inc. by 0.4% in the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock worth $1,912,000 after buying an additional 2,007 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its stake in icad inc. by 822.3% in the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock worth $586,000 after buying an additional 124,612 shares in the last quarter. Institutional investors and hedge funds own 25.16% of the company’s stock.
Separately, Laidlaw reaffirmed a “buy” rating and set a $11.00 target price on shares of icad inc. in a report on Tuesday, July 25th.
icad inc. Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
What are top analysts saying about icad inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for icad inc. and related companies.